Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).
Tuberculosis is one of the main causes of mortality with 1.5 million deaths a year worldwide. The growing emergence of multi- and extremely resistant strains highlights the urgent need of novel antibiotic strategies. Ethionamide, interfering with the mycobacterial membrane biosynthesis, is used in second-line treatment. This molecule is a prodrug, which requires activation by EthA. The patent described in this evaluation (WO2014049107A1) claimed a new family of molecules and their use as antibiotic treatment against mycobacteria such as Mycobacterium tuberculosis, M. leprae and atypical mycobacteria, either as a single active agent or in combination with antibiotics activable by EthA pathway.
Unité de Service et de Recherche CNRS - Pierre Fabre n°3388 ETaC - Epigenetic Targeting of Cancer , CRDPF, 3 avenue Hubert Curien, 31035 Toulouse Cedex 01 , France marie.lopez@etac.cnrs.fr.
Dany
D
Pechalrieu
Marie
M
Lopez
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D006801:Humans; D009164:Mycobacterium Infections / Q000188:drug therapy / Q000382:microbiology; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D010330:Patents as Topic; D011355:Prodrugs; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology
D000995:Antitubercular Agents; D011355:Prodrugs
EthA activation pathway; EthR-interacting molecules; anti-infectious; mycobacterial infections